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CObjectives: This study aimed to identify the causes of the nonadher-
ence (NA) of German patients to their prescribed medication. In the
ourse of the investigation, the NA risk profiles resulting from the
ombination of the various causes were identified. Methods: Two
cross-sectional surveys with a total of 1517 patients (comprising 1177 pa-
tients contacted by telephone and forming survey 1 and a different set of
340patients interviewed in-depthand face-to-face formingsurvey2)were
conducted. Self-reported NA was measured by the generic Morisky Med-
ication Adherence Scale (MMAS). Survey 1 used a four-item MMAS and
Survey 2 an eight-itemMMAS. Results: Approximately 35% to 40% of the
patients can be described as nonadherent. In survey 1, a few causes ex-
plain the NA (chronic disease, younger age, and fewer medications re-
quired to be taken). Themore detailed survey 2 shows that the existence
of intentional NA has considerably more influence than any other causal
factors. Positive medication beliefs, a positive mood, and a good patient- O
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doi:10.1016/j.jval.2011.06.002octor relationship reduce the NA risk. Furthermore, patients who are
asily able to recognize the correct medication, as evidenced by ability to
orrectly identify the packaging, have a reducedNAprobability. Concern-
ng additive risk, patients who are chronically ill but display no other
auses of risk have an NA probability of 10.4%. By contrast, in patients
isplaying all the identified causes of risk, the rate increases to 93.9%.
onclusions: About one-third of patients can be classified as nonad-
erent. Intentional/medication-based NA causal factors explain the
A considerably better than do socioeconomics. The existence ofmore
han one cause of risk considerably increases the NA risk of a patient.
eywords: nonadherence, noncompliance, nonadherence/noncompli-
nce causes.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Medication-based nonadherence (NA) in chronic indications can
be defined as the extent to which a person’s drug-taking behavior
does not correspond to instructions from a health-care provider
[1–3]. Because approximately 30% to 50% of patients are affected
by it [2,4,5], NA is a considerable challenge. NA significantly influ-
ences clinical (surrogate) parameters [3,6] and long-termmortality
7] and increases health-care costs [8,9]. By contrast, there exists
often sobering evidence of the lack of efficacy of intervention pro-
grams. Only 50% of such programs/interventions are capable of
significantly reducing the NA of patients, and only a third of the
interventions improve clinical surrogate parameters [4,10]. There
are multiple causes of this state of affairs. However, one of the
most important reasons for the lack of effectiveness is that only a
very few adherence programs are based on a careful audit of the
patient-specific causes for NA (adherence barriers). If NA causes
were known in detail, they could be used, possibly even on an
individual or a patient cluster basis, to develop specific barrier-
reducing measures [10–14]. Detailed knowledge of the relevant
causes of NA is therefore an important precondition for increasing
the effectiveness of adherence programs.
* Address correspondence to: ThomasWilke, Institut für Pharmak
of Applied Sciences), PF 1210, 23952 Wismar, Germany.
E-mail: thomas.wilke@hs-wismar.de.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.A variety of factors are discussed as potential causes of NA [5].
More recent classification methods of NA causes distinguish in
particular intentional and unintentional factors [10,15,16]. In the
main, we follow this approach, which distinguishes five groups of
causal factors (Fig. 1). The evidence to date concerning the impor-
tance of these five factors in explaining NA can be summarized as
follows:
● Within the medication-based factors, the complexity of medi-
cation regimens [17–19] and the possibility of side-effects
[11,20] are the main contributors.
Direct and indirectmedication-related costs that patients have
to bear (e.g., copayments, waiting times, long journeys to reach
the doctor) are the most important health care–related factors
[21–24].
Sociodemographic factors play only a small part [25,26]. In ad-
dition, particularly with regard to aging, there is not a consis-
tent direction of influence on NA [10].
Factors leading to unintentional NA have to date only been
sporadically investigated. Factors such as depression [27,28],
dementia, or increased forgetfulness or carelessness [29–31], or
nomie und Arzneimittellogistik, University of Wismar (University
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
●n
o
a
t
a
t
c
c
t
o
r
l
p
w
[
a
m
t
p
t
s
f
v
s
c
s
i
i
l
m
f
p
t
i
1093V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 9 2 – 1 1 0 0a lower than average level of health literacy [32] increase both
the extent and probability of the occurrence of NA.
Recently, there has been much more attention paid to factors
in the context of intentional NA. Even though many questions
remain unresolved, it is apparent that these factors are capable
of explaining a considerable part of the NA [10]. In this regard,
negative general attitudes and negative medication beliefs
[33,34] aswell as inadequate coping behavior [35–38] and a poor
relationship with health-care providers [26,39,40] are the most
important.
Previous research concerning NA causes has two central weak-
esses: 1) Multivariate analysis is used only rarely [10,41]. On the
ne hand, this applies to numerous articles written on the basis of
dministrative/claims-based data [42]. Due to the data situation,
hese are only as a rule able tomeasure the sociodemographic and
few of the indication- andmedicine-based NA causes [43,44]. On
he other hand, even studies that have examined further NA
auses only examine a few or only one specific factor [4,10], typi-
ally, medication-related factors such as the number of medica-
ions to be taken daily were analyzed in considerable detail with-
ut consideration of other potential NA causes [45]. Therefore, the
eciprocal effects between the factors and their additive effects are
argely unknown. 2) Numerous publications concerning NA, and
articularly survey-based investigations, have used methodically
eak NAmeasurement instruments that have not been validated
46,47]. Quite regularly, a single simple direct question failing to
pply even rudimentary techniques of psychometric analysis and
easurement development is used instead of a validated and de-
ailed self-report to measure NA [48–51]. Self-report instruments
er se have their limitations, such as respondent bias and errors in
he recall of behavior [48]. In addition, in research designs using
imple direct questions about medication that has possibly been
orgotten, there is the potential for activating what the inter-
iewee sees as socially desirable answer behavior [49,50]. More
ophisticated NA self-report questionnaires use indirect, nonac-
usatory questioning techniques tominimize the tendency to give
Fig. 1 – Illustration shows important nonadherence causes d
groups.ocially desired answers. Therefore, validating NA measurementnstruments before using them or using only previously validated
nstruments is strongly recommend.
In the context of the research intoNAcauses and its current chal-
enges detailed previously, this study reports the results of two Ger-
an surveys (a telephone survey anda subsequent in-depth face-to-
ace survey). It aimed to identify the factors that can be used to
redict the NA of German patients to their prescribed medication
herapy. In the course of the investigation, theNA riskprofiles result-
ng from the combination of the various causes of risk are identified.
Methods
This article reports the results of two cross-sectional surveys that
included a total of 1577 patients. In the first survey, 1177 patients
were interviewed by a structured telephone interview. This survey
was originally conducted to assess the extent of NA in outpatient
thromboprophylaxis after major orthopedic surgery [34]. The in-
terviewed patients were drawn from 22 German acute or rehabil-
itation orthopedic clinics (informed consent). The potential sam-
ple included all the patients in these clinics who were scheduled
for or had already had hip or knee arthroplasty and whowere able
to answer questions in a telephone interview (consecutive recruit-
ment) 40 to 45 days after surgery. The initial sample size (1771
patients) was reduced because 16% (276 patients) refused to give
their informed consent or could not be interviewed because of
their poor health status. Consequently, interviews were per-
formed with 1495 patients. The data gathered from 78.7% of these
patients (1177 patients) were included in a further analysis be-
cause the patients confirmed that they were taking regular, at
least daily, medication. Two focus groups, one with five members
and one with four members, were used to pretest the question-
naires in terms of comprehensibility and practicability. Some
questions were found to be difficult to understand in a telephone
interview and were therefore rewritten. The interviews were con-
ducted by trained interviewers, each of whomhad previously con-
ducted three to five test interviews under supervision. The super-
ssed in the literature, and their classification into fiveiscuvised interviewswere audio recorded and subsequently evaluated
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1094 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 9 2 – 1 1 0 0in the presence of the interviewers to give performance feedback
and increase the learning effects. The interviewers had to learn
the content of the questionnaire before conducting an interview
and were educated in the normal treatment of a patient who had
undergonemajor orthopedic surgery before release from the acute
hospital. The interviewers did not have medical degrees because
the level of medical knowledge necessary to conduct the inter-
views was not advanced. The data were collected in real time in a
Microsoft Access databank. The real-time collection was based on
an online tool developed for this purpose, which included pre-
defined data entry fields to reduce the risk of data entry errors.
Furthermore, an audio recording of each interview was also made
to provide help should discrepancies later arise. During the study,
these recordingswere also used to supervise the interviewers. The
average interview was conducted on day 41 after orthopedic sur-
gery and lasted approximately 10 to 15 minutes. The question-
naire consisted of 30 questions.
The second in-depth face-to-face survey was conducted ex-
plicitly to promote the aims of this study, and itsmain focuswas to
collect additional information on potential NA causes. This survey
was conducted with 340 pharmacy customers in 17 German phar-
macies, again using pretested questionnaires. The pretest was
conducted with 20 patients in one pharmacy. The patients who
took part in the second survey were not the same ones who took
part in the first survey. As in the first survey, only patients on
regular, at least daily,medicationwere included in the survey. The
interviews were conducted by trained interviewers without any
medical degrees. Again, the interviewers first conducted three to
five test interviews under supervision. All the interviews were su-
pervised, this time, however, bymeans of the completed question-
naires instead of audio recording. The collected data was taken
down in writing and later transferred to a Microsoft Access data-
bank. Double data entry was conducted, to minimize errors. An
independent supervisor checked all the data entries to control for
consistency and to identify unexpected values. The people se-
lected to be interviewed were average patients visiting a German
pharmacy. This was achieved by each interviewer being given an
age and sex distribution ratio identical to the average distribution
of these characteristics at the particular pharmacy and told to
follow it in selecting interviewees. After giving their informed con-
sent, the patientswere interviewed in the participating pharmacy,
either immediately or at a later date of their choice. Each interview
lasted 20 to 30 minutes and was based on a questionnaire with 26
questions. All the variables (surveys 1 and 2) included in this anal-
ysis are listed in Table 1.
In each of the surveys, the general medication-based adher-
ence of the interviewees was measured by a self-report. This was
donewithout considering particular indications ormedications. In
survey 1, theNAmeasurement instrument usedwas the four-item
Morisky Medication Adherence Scale (MMAS-4) [52], and in survey
2, the eight-item MMAS (MMAS-8) [6] was used. (Use of the MMAS
s protected by US copyright laws. Permission for use is required.
icensure agreement is available from Donald E. Morisky, ScD,
cM,MSPH, Professor, Department of CommunityHealth Services,
CLA School of Public Health, 650 Charles E. Young Drive South,
os Angeles, CA 90095-1772.) Both indices are validated measure-
ent instruments in current use. The existence of NA was estab-
ished by the scoring logic of the MMAS used. In survey 1, every
atient who reached an index score of 4 was classified as non-
dherent [52]. In survey 2, every patient who reached an index
core of 6 was classified as nonadherent [6].
Table 1 gives an overview of sociodemographic characteristics
s well as additional information obtained during the surveys and
otentially capable of explaining the occurrence of NA. The infor-
ation gathered in survey 1 is suitable for analyzing the influence
f sociodemographic factors on NA. By contrast, survey 2 allows
he detailed evaluation of the influence of other causal factors mn possibly intentional/medication-based NA (Fig. 1). The sys-
ematic recording of these factors was conducted using vali-
ated measurement instruments. However, due to the limited
ime available for the interviews, these instruments were used
n a shortened/summarized form: the medication beliefs sec-
ion was reduced to four questions, a selection from the Beliefs
bout Medicines Questionnaire (BMQ), an instrument using
-point Likert scales [33]. In this study, only the general part of
he German validated version of the BMQ [53] was considered.
his part consists of eight questions that reflect general harm
nd general overuse scales. Because the focus of our interest
as on the general harm context, we chose the four questions in
he BMQ that had in the validation study attained the highest
actor load for the general harm scale [33]:
Medicines do more harm than good.
People who take medicines should stop their treatment for a
while every now and again.
Most medicines are addictive.
All medicines are poisons.
he doctor-patient relationship was examined using a question-
aire from DiMatteo [54]. This questionnaire has not yet been val-
dated in Germany, so after translation into German, it was back-
ranslated and the German version adjusted until a match was
chieved. The emotional state of the interviewees was deduced by
he Self-Assessment Manikin (SAM) concept [55]. The SAM ques-
ionnaire consists of three panels (valence, arousal, domains). In
his survey, only the first panel was used because only the general
ood was to be measured. The state and level of the relationship
etween customers and pharmacists as well as possible practical
ifficulties experienced by patients withmedication or its packag-
ng were documented by using the following questions (4- or
-point Likert scales):
Relationship between customers and pharmacists
I believe that my pharmacist helps me.
I believe that my pharmacist understands me.
I think that my pharmacist gives clear instructions.
Difficulties experienced by patients with medication/packaging
How difficult is it to distinguish the medicines on the basis of
their packaging?
How difficult is it to find how much of the medicine to take?
How difficult is it to open the package?
How difficult is it to read the leaflet?
hese last questions were developed specifically for this study
ecause as far as the authors know, there was not a preexisting
alid and practicable instrument available to assess these poten-
ial NA causes.
The data were subjected to multivariate analysis (logistic re-
ression) using NA as the dependent variable. To test for depen-
encies due to clustering effects (22 centers in survey 1, 17 centers
n survey 2), each regression estimate was redone using general-
zed estimating equation (GEE) methods [56]. The differences be-
ween the logistic regression estimates and the GEE estimates,
owever, were very small so we chose to report only the logistic
egression estimate results.
In principle, all the documented information was included as in-
ependent variables in the first model calculations. Multivariate re-
ression analysis was carried out using backward stepwise elimina-
ion to determine themost parsimonious factors associatedwithNA
robabilities. In the backward stepwise iterations, regression terms
t a significance level of P  0.10 were successively eliminated. All
odels, however, were adjusted for sex, living circumstances, and
1095V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 9 2 – 1 1 0 0Table 1 – Collected variables and descriptive statistics.
Variable Survey 1 Survey 2
N 1177 340
Mean age in years Ø 68.5 (range 21–94; SD 9.002) Ø 55.8 (range 17–90; SD 17.042)
Sex, no. (%)
Female 720 (61.2) 218 (64.1)
Male 457 (38.8) 122 (35.9)
Chronic diseases (more than one answer possible), no. (%)
None 436 (37.0) 108 (31.8)
Hypertension 365 (31.0) 119 (35.0)
Diabetes (both types) 152 (12.9) 51 (15.0)
Rheumatism 37 (3.1) 11 (3.2)
Asthma/allergy 35 (3.0) 44 (12.9)
Other 294 (25.0) 138 (40.6)
Living circumstances, no. (%)
Living alone 270 (22.9) 93 (27.4)
Living with spouse/life partner 794 (67.5) 247 (72.6)
Living with children 84 (7.1) —
Other circumstances 29 (2.5) —
Highest achieved education level, no. (%)
Without any formal apprenticeship 160 (13.6) 35 (10.3)
Completed apprenticeship 806 (68.5) 225 (66.2)
University degree 152 (12.9) 80 (23.5)
Other degrees 59 (5.0) —
Current working status, no. (%)
Blue-collar worker — 16 (4.7)
White-collar worker — 107 (31.5)
Entrepreneur — 24 (7.0)
Pensioner — 146 (43.0)
Unemployed — 12 (3.5)
Other — 35 (10.3)
Emotional state of respondents at the time of the interview
(based on Manikin scale)
Very good — 82 (24.1)
Good — 158 (46.5)
Moderate — 80 (23.5)
Bad — 16 (4.7)
Very bad — 4 (1.2)
Information not collected — —
No. of different drugs taken per day
Mean no. 4.1 (range 1–16, SD 2.671) —
No. of prescribed medications
Mean no. — 3.1 (range 1–15, SD 2.456)
Dosing frequency prescribed medications
More than once daily — 150 (47.0)
Once daily — 155 (48.6)
At least once a week — 10 (3.1)
Less than once a week — 4 (1.3)
No. of OTC medications taken
Mean no. of drugs taken per day — 2.3 (range 1–8, SD 1.407)
Dosing frequency OTC medications
More than one time daily — 29 (11.3)
Once daily — 97 (37.9)
At least once a week — 41 (16.0)
Less than once a week — 89 (34.8)
MMAS-4 score
1 13 (1.1) —
2 101 (8.6) —
3 343 (29.1) —
4 720 (61.2) —(continued on next page)
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interviewee (listwisedeletion), theentire setwasdiscarded.Asacon-
sequence, the data from eight patients were excluded from themul-
tivariate analysis of survey 2. A significance level of 0.05 was chosen
for analysis.
Survey 2 coversmany potential risks of NA. To quantify the addi-
tive risk that may occur in the presence of several of these risks, in
Table 1 (continued).
Variable
MMAS-8
High adherence (score  8)
Moderate adherence (score 6–7)
Low adherence (score 6)
Doctor-patient relationship (patient’s perspective)
Physician takes the lead without previous discussion with patient
Physician takes the lead as previously discussed with the patient
Physician and patient act as equal partners
Information not collected
Pharmacy-patient relationship (patient’s perspective index: 3 
good relationship, 12  bad relationship)
3–6
7–9
10–12
Information not collected
Medication (beliefs index: 4  positive beliefs,
20  negative beliefs)
4–8
9–12
13–16
17–20
Information not collected
Difficulties with medication packages
Identification of different drugs
Very difficult
Difficult
Moderate
Easy
Very easy
Information not collected
Reading medication dosage
Very difficult
Difficult
Moderate
Easy
Very easy
Information not collected
Opening packages
Very difficult
Difficult
Moderate
Easy
Very easy
Information not collected
Reading leaflets
Very difficult
Difficult
Moderate
Easy
Very easy
Information not collected
The table shows all variables that were included in the data set and
MMAS-4, four-item Morisky Medication Adherence Scale; MMAS-8, e
average.whatever combination, all the significant independent variables (P0.05) from the multivariate regression model from survey 2 were di-
chotomized. Subsequently, the estimation of the occurrence of NA
was repeated on the basis of the resulting dichotomized explanatory
parameters and for every interviewee. The results of themodelwere
used to predict the probability of each of the interviewees being non-
adherent. On the basis of these probabilities, the average risk of the
occurrence ofNAwas estimated for each group/each combination of
Survey 1 Survey 2
— 97 (28.5)
— 123 (36.2)
— 120 (35.3)
— 34 (10.0)
— 91 (26.8)
— 212 (62.3)
— 3 (0.9)
— 325 (95.6)
— 11 (3.2)
— 2 (0.6)
— 2 (0.6)
— 123 (36.2)
— 90 (55.9)
— 24 (7.0)
— 0 (0.0)
— 3 (0.9)
— 8 (2.4)
— 33 (9.7)
— 63 (18.5)
— 131 (38.5)
— 101 (29.7)
— 4 (1.2)
— 13 (3.8)
— 67 (19.7)
— 73 (21.5)
— 117 (34.4)
— 66 (19.4)
— 4 (1.2)
— 7 (2.0)
— 27 (7.9)
— 83 (24.4)
— 110 (32.4)
— 109 (32.1)
— 4 (1.2)
— 61 (17.9)
— 101 (29.7)
— 84 (24.7)
— 61 (17.9)
— 29 (8.6)
— 4 (1.2)
analyzed to identify NA causes.
tem Morisky Medication Adherence Scale; OTC, over-the-counter; Ø,were
ight-ithe independent risk factors.
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Table 1 shows the interviewees in survey 1 to be a relatively older
group (average age in survey 1 was 68.5 years compared with 55.8
years in survey 2, P  0.001). This is explained by the fact that
urvey 1 was concerned with average orthopedic patients,
hereas survey 2 was concerned with average German pharmacy
ustomers. Both groups of interviewees are characterized by ex-
ensive dependency on medication as well as the occurrence of
hronic disease (63.0% in survey 1 and 68.2% in survey 2).
In the first survey, the mean MMAS-4 score was 3.50 (SD 0.699)
nd 38.8% of the patients reached an index score of 4 (values 4
ndicate NA). In the second survey, the mean MMAS-8 score was
.14 (SD 1.954) and 35.3% of the patients reached anMMAS score of
6 (values6 indicate NA). Both of these analyses revealed 35% to
0% of the patients to be affected by NA.
The results of the multivariate analysis of potential NA causes
n survey 1 makes it clear that only a few factors are capable of
xplaining the probability of NA in patients (Table 2). These factors
re the occurrence of chronic disease, relative youth, and having
nly a few medications to take. Consequently, the explanatory
ower of the model developed here is limited (Nagelkerke R2 is
0.061). Education level, sex, and living circumstances of the patient
are not significant predictors of NA (P  0.100). These parameters
remained in the estimate as control variables, but are not shown in
Table 2 as relevant NA causes.
The multivariate analysis conducted on the basis of the data in
survey 2 explains amuch larger part of the self-reportedNA than the
model based on survey 1; R2 is almost six times higher than in survey
.The resultsof thefirst analysis regarding the roleof chronicdisease
nd age are replicated (Table 2). By contrast, the number of medica-
Table 2 – Multivariate logistic regression estimates of facto
Age in years
Existence of chronic disease
No
Yes
No. of medications to be taken
Mood (5-point Likert scale: 1  very good; 5  very bad)
Patient-doctor-relationship (1  physician and patient act as equal
partners; 3  physician takes the lead without previous
discussion with patient)
Patient-pharmacy relationship: “Pharmacy gives effective/
understandable explanations” (4-point Likert scale: 1  fully
agree; 4  fully disagree)
Negative medication beliefs: “People who take medicines should
stop their treatment for a while every now and again” (5-point
Likert scale: 1  fully disagree; 5  fully agree)
Difficulties with medication packages: identification of different
drugs (5-point Likert scale: 1  no difficulties; 5 major
difficulties)
Table shows results of logistic regression estimates.
CI, confidence interval; OR, odds ratio.
* A backward elimination method was performed including all varia
models.
† Eight patients without complete data for all relevant independent
‡ Derived from the logistic models are adjusted for sex, living circum
§ Reference group.ions that have to be taken has no independent influence. Causes
hat can be classified as part of the context of intentional NA or are
edication related, however, are both important and highly signifi-
ant. These causes are negativemedication beliefs (proposition: peo-
lewho takemedicines should stop their treatment for awhile every
ow and again; P  0.001), a negative mood or fundamental pessi-
ism (P 0.005) as well as a low level of trust in doctors (P 0.001),
nd all increase theprobability of a person classifyinghim- or herself
s nonadherent. A factor that as far as the authors know has not
reviously been investigated in detail can be added to the list: the
ifficulties experiencedbypeople indistinguishingbetweenmedica-
ions and medication packaging and understanding the contents of
he packaging. The results show that if people find it difficult to iden-
ify their requiredmedication bymeans of the packaging, they have
significantly higher probability (odds ratio 1.708, P 0.001) of clas-
ifying themselves as nonadherent. The following variables did not
ignificantly explain the measured NA of respondents (P 0.100):
● Current working status
● Number of different drugs taken per day
● Belief that medicines do more damage than good
● Belief that most medicines are addictive
● Belief that natural remedies are safer than medicines
● Difficulty reading medication dose from medication packages
● Difficulty opening medication packages
● Difficulty reading leaflets
As in survey 1, education level, sex, and living circumstances of the
patient are not significant predictors of NA (P  0.100) Again, these
parameters remained in theestimateas control variables, but arenot
shown in Table 2 as relevant NA causes.When the explanatory vari-
plaining nonadherence.
del summary* (N  1177):
survey 1
Model summary* (N  332†):
survey 2
Nagelkerke R2
0.061
Nagelkerke R2
0.352
OR (95% CI)‡ P value No. OR (95% CI)‡ P value
0.965 (0.951–0.978) 0.001 332 0.980 (0.963–0.997) 0.023
1.000§ 0.031 105 1.000§ 0.037
1.333 (1.027–1.731) 227 1.952 (1.042–3.657)
0.920 (0.876–0.967) 0.001
332 1.601 (1.157–2.217) 0.005
332 2.027 (1.336–3.074) 0.001
332 1.530 (0.923–2.538) 0.099
332 2.195 (1.519–3.171) 0.001
332 1.708 (1.299–2.244) 0.001
hown in Table 1. Variables with P value  0.10 remained in the final
bles were excluded from the analysis.
ces, and education.rs ex
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as significant and independent contribute cumulatively to the NA
risk (Fig. 2). Only 2.0% of the patients did not exhibit any of the six
identified causes. For 75.5%,more than one causal factorwas impor-
tant, whereas for 22.5%, only onewas important. It follows thatmul-
ticausality is the rule and not the exception. In the case of interview-
ees who are merely chronically ill without having additional causes
of risk, their NA probability is on average 10.4%. The combination of
chronic illness with any of the remaining five factors increases the
probability of NA to at least 19.3% or to a maximum of 29.9%. In our
sample, in which an interviewee displayed all the identified NA
causes, the NA probability increased to 93.9% (Fig. 2).
Discussion
This study began with the intention of identifying the factors that
can be used to predict the NA of German patients to their pre-
scribedmedication therapy. In the course of the investigation, the
NA risk profiles resulting from the combination of the various
causes of riskwere identified. As far as the authors are aware, ours
is the largest study of medication-based NA and its causes con-
ducted in Germany. The results show that on the basis of self-
reports, approximately a third of patients can be considered to be
Fig. 2 – Illustration (on the basis of the multivariate causal a
various risk factors (stand-alone as well as in combination).
combination class (based on the combination of NA causes i
additional NA risk related to the added causal factor.nonadherent. Sociodemographics alone do not explain the NA aswell as factors that can be thought of as part of the context of
intentional/medication-related NA.
The authors acknowledge some limitations of the study. First,
neither of the surveys is representative of the average chronically
ill German patient. Nevertheless, the analyzed groups are samples
characterized by a high average rate of medication dependence
and occurrence of chronic disease. Because neither sex nor multi-
ple morbidities represent significant explanations of the occur-
rence of NA, the samples analyzed here do not appear to display
bias. Only the relative youth of the participants in survey 2 is ca-
pable of causing an overestimation of the extent of NA in this
database. Second, due to the limited time available for each inter-
view that arose on organizational grounds and the design of the
questionnaire, it was not possible to record data concerning all
theoretically possible NA causes. The variables not recorded con-
cern the health beliefs of the interviewees [57,58], the approach to
disease/coping behavior [35], the influence of the health literacy
[32], patients’ copayments [59,60], and specific indication/medica-
tion factors including the side effects of particular medicines. In
addition, neither survey was used as a basis to analyze any factors
describing explicit unintentional NA causes and therefore objec-
tive adherence barriers. On the other hand, survey 2, in particular,
even in its existing form, is a database for the explanation of NA of
sis in survey 2) of the nonadherence (NA) connected to
t gray areas indicate the base case in each risk
e previous class), whereas dark gray areas indicate thenaly
Ligh
n tha size and form that is internationally relatively rare. Third, the
1099V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 9 2 – 1 1 0 0reliance on self-reports is one of the weaknesses of our study.
The available evidence shows that self-reporting underesti-
mates the extent of NA [61–64]. In this regard, the inclusion of
other indicators such as administrative data or Medication Event
Monitoring System/pill counts would considerably increase the
validity of the NA measurement [34,65,66]. Limited data availabil-
ity, however, is the challenge here. Nevertheless, the self-report-
ing measures used are good and validated instruments. Both sur-
veys used scales that have been validated (discriminant validity)
with regard to social desirability [6,52]. Fourth, this investigation
only concerned medication-based NA. Health outcomes and
health-care costsmay both be influenced by other elements of the
health-care provision system. Our study describes only one, al-
though important, aspect of health-care provision.
The results presented here are compatible with other findings
in the literature. The extent of self-reported NA is comparable to
that found in other studies [2,10,44,67]. The results of our causal
analysis provide confirmation of the relevance of the direction of
themore recent NA research, which emphasizes intentional/med-
ication-related NA [10,30,68,69]. Our study confirms that several
intentional factors exert independent influence on the NA proba-
bility. Survey 2 shows that in cases in which one patient displays
all the factors in combination, the result is almost certainly NA.
Interestingly, the following factors that are discussed as NA predic-
tors in the literature donot explain anyNA in our samples: the sex or
education of patients, number ofmedications taken (survey 2), occu-
pational status, specific chronic diseases, or relationship to pharma-
cists/pharmacies. Evidently, intentional factors found in our sample
tobeNApredictors exert suchadominant influenceonNAthat there
remains no independent influence of those other factors.
The results of our study provide important starting points for
future research as well as for the further development of adherence
programs. Future research into NA causes should focus on three is-
sues: 1) whether the interpretation of different NA causes depends
on specific care or patient-related factors (patient segmentation); 2)
what the degree of interaction with other NA explanations is; and 3)
whether important factors explaining NA change over the course of
time and are thereby the cause of the well-known phenomenon of
decreasing persistence of patients after initial treatment [41,70].
The clinical and health economics effectiveness of adherence
programs depends in large part on the extent to which important
adherencebarriers canbeaddressed.Our results show that causes of
intentional/medication-relatedNAoccupy a keyposition in this con-
text. Reducing intentional NA requires thorough and in-depth
knowledge about patients’ views and preferences as well as exten-
sive knowledge about how interactions between patients and other
health-care providers influence possible NA [4]. Most of the adher-
ence interventions used/tested so far, however, fail to address the
causes identified in our surveys as the most important reasons for
NA [4,71]. The promotion of positive medication beliefs, a positive
view of illness and therapy, an independentmeasurement and opti-
mization of the doctor-patient relationship, and the optimization of
ways of dealing with the medication packaging appear to be ele-
ments that are essential for adherence intervention effectiveness.
Lessons drawn from these conclusions should be combinedwith ex-
isting knowledge concerning factors already known to partly explain
the effectiveness of adherence interventions. The mere provision of
information does not reduce the NA, but providing training to pro-
mote the active involvement of patients can be effective [72,73]. Fur-
thermore, a combination of more than one intervention measure is
more effective than any single measure alone [4,74]. Finally, long-
term programs are more effective than single interventions [72,75].
Obviously, addressing intentional/medication-related NA under the
factors just named as leading to success increases the complexity
and the cost of an adherence intervention. On the other hand, inter-
vention programs that do notmanage to sustainably reduce NA dueto multiple causes will not be cost-effective, no matter how low the
intervention costs are.
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